IGF1R
Insulin-like growth factor 1 receptor
As of the edition of 20 October 2026, IGF1R (insulin-like growth factor 1 receptor, UniProt P08069) has 21 drugs tested at it and 28 companies on the list, 13 on route A and 5 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P08069
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 46
- Disease areas
- Cancer; Hormones; Digestive system; Inherited and neonatal; Immune system; Lungs and airways; Eye; Skin and connective tissue
- Registered trials of its drugs
- 230
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 5 |
| Active | 2 |
| Went quiet | 4 |
| Stopped | 8 |
| Status not established | 2 |
| Total | 21 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Cixutumumab | Went quiet | Phase 2 | none listed |
| Ganitumab | Stopped | Phase 3 | none listed |
| Teprotumumab | Marketed | Phase 4 | Ends 2032 |
| Linsitinib | Active | Phase 3 | none listed |
| Figitumumab | Stopped | Phase 3 | none listed |
| Mecasermin | Marketed | Phase 3 | Ended 2017 |
| Dalotuzumab | Went quiet | Phase 2 | none listed |
| Veligrotug | Marketed | Phase 4 | Ends 2038 |
| BMS-754807 | Stopped | Phase 2 | none listed |
| MHB018A | Active | Phase 3 | none listed |
| AXL-1717 | Stopped | Phase 2 | none listed |
| Robatumumab | Stopped | Phase 2 | none listed |
12 of 21 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 13 |
| Route B | 5 |
| Engaged | 4 |
| Undetermined | 6 |
| Total on the list | 28 |
The other 25 companies at IGF1R
In the product28 companies in all; 25 are not named here, and no score is.
See the 28 companies at IGF1R, ranked, with the facts behind eachRequest access. Nothing is shown until you do.